Drug Drug Interaction Clinical Trial
Official title:
A Phase 1, Open-Label, Two-Period,Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam
Verified date | November 2023 |
Source | Guangdong Raynovent Biotech Co., Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a single-center, open label phase I clinical study to characterize the DDIs potential of ZSP1273 With Warfarin and Midazolam in Chinese healthy participants. This study also aims to evaluate the safety and tolerability of ZSP1273 in the presence of Warfarin and Midazolam.
Status | Completed |
Enrollment | 28 |
Est. completion date | August 4, 2023 |
Est. primary completion date | July 21, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Adult, male and female participants, 18 to 55 years of age, inclusive, at first Check-In Visit; 2. Body mass index (BMI) =19 to =26kg/m2 and total body weight >50 kg(male) or >45kg(female) at Screening (calculated as a function of measured height and weight according to the formula, BMI = kg / m2 where m2 is height in meters squared); 3. Ability to understand and willingness to sign a written informed consent form; 4. Normal physical examination, vital signs, 12-lead ECG, Chest X-ray images (anteroposterior) and clinical laboratory values, or any abnormality that is non-clinically significant. Exclusion Criteria: 1. Participants with a history of hypersensitivity to study drug(ZSP1273,warfarin, midazolam) or any component of study medication; 2. Participants with a history of and/or signs and symptoms of current abnormal hemostasis or blood dyscrasia or abnormal prothrombin time (PT), international normalized ratio (INR), or activated partial thromboplastin time at screening; 3. Smoking more than 5 cigarettes per day within 3 months prior to screening,or who cannot stop using any tobacco products during the study period; 4. Participants who donated blood/bleeding profusely (> 400 mL) 3 months prior to randomization; 5. Those with clinically significant ECG abnormalities, or QTcF > 450ms in men and QTcF > 470ms in women; 6. Participants who test positive at screening for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody or Syphilis spirochete-specific antibodies (TPPA); 7. Participants who test positive at Screening and/or admission (Day -1) for alcohol abuse. 8. Females who are pregnant, lactating, or likely to become pregnant during the study. 9. History of dysphagia or any gastrointestinal disorder that affect absorption |
Country | Name | City | State |
---|---|---|---|
China | the Second Affiliated Hospital of Guangzhou Medical University | Guangzhou |
Lead Sponsor | Collaborator |
---|---|
Guangdong Raynovent Biotech Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | S-warfarin Maximum Plasma Concentration [Cmax] | To assess the effect of steady-state ZSP1273 on the pharmacokinetic (PK) of a single dose of S-warfarin | Day1 to Day28 | |
Primary | Midazolam Maximum Plasma Concentration [Cmax] | To assess the effect of steady-state ZSP1273 on the pharmacokinetic (PK) of a single dose of midazolam and its active metabolite alpha-hydroxymidazolam | Day1 to Day28 | |
Primary | S-warfarin Area under the curve[AUC0-inf] | To assess the effect of steady-state ZSP1273 on the pharmacokinetic (PK) of a single dose of S-warfarin | Day1 to Day28 | |
Primary | Midazolam Area under the curve[AUC0-inf] | To assess the effect of steady-state ZSP1273 on the pharmacokinetic (PK) of a single dose of midazolam and its active metabolite alpha-hydroxymidazolam | Day1 to Day28 | |
Secondary | Number of participants with adverse events and serious adverse events | To assess the safety and tolerability of ZSP1273 following single and multiple-dose administration with and without midazolamin+S-warfarin in healthy participates | Day1 to Day28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05574374 -
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04557397 -
Fruquintinib CYP3A Inhibitor and Inducer Study
|
Phase 1 | |
Completed |
NCT06031454 -
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin
|
Phase 1 | |
Completed |
NCT05137600 -
A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06119958 -
Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05812404 -
Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04606537 -
Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04939467 -
Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04542252 -
Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects
|
Phase 1 | |
Enrolling by invitation |
NCT06037564 -
B-free Multistage Trial
|
Phase 4 | |
Completed |
NCT05123820 -
Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470
|
Phase 1 | |
Recruiting |
NCT04840862 -
Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor
|
Phase 4 | |
Completed |
NCT04814498 -
Drug-Drug Interaction (DDI) Study in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01350921 -
Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03103568 -
A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04840641 -
Flucloxacillin as an Inducer of CYP-enzymes
|
Phase 1 | |
Completed |
NCT05860114 -
Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)
|
Phase 1 | |
Completed |
NCT05845567 -
The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
|
Phase 1 | |
Completed |
NCT05304845 -
Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04776499 -
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers
|
Phase 1 |